Botulinum Toxin A in the Treatment of Hemifacial Spasm

Last updated: October 11, 2017
Sponsor: Tongji University
Overall Status: Trial Status Unknown

Phase

N/A

Condition

Hemifacial Spasm

Pain (Pediatric)

Treatment

N/A

Clinical Study ID

NCT03306940
14SG21
  • Ages 18-80
  • All Genders

Study Summary

Hemifacial spasm patients who received botulinum toxin A injection were divided into two groups. Group A received unilateral injection while group B received bilateral injection. Patients completed follow-up A researcher record facial videos and analyzed facial symmetry and completed 3 scales.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • clinical diagnosis of hemifacial spasm

  • Scott grading III to IV

  • hemifacial spasm duration of half or more years

  • last botulinum toxin A application at least 3 months before the start of the study

Exclusion

Exclusion Criteria:

  • history of facial trauma, congenital facial asymmetry, facial nerve microsurgicaldecompression

  • bilateral hemifacial spasm

  • allergies to botulinum toxin A or to any component of the drug

  • previous treatment with botulinum toxin A fewer than 3 months

  • the use of drugs that could interfere with neuromuscular transmission or spasm

Study Design

Total Participants: 50
Study Start date:
October 02, 2017
Estimated Completion Date:
August 31, 2018

Study Description

Hemifacial spasm patients who received botulinum toxin A injection were divided into two groups.Patients of unilateral group were injected to the affected side and the dose of botulinum toxin A was 2.5-3.75 units/per site. Patients of bilateral group were injected to the affected side with dose of 2.5-3.75 units/per site and the normal side was injected with dose of 1.25 units/per site.

3 scales for measurement were used.

Connect with a study center

  • Shanghai Tongji Hospital

    Shanghai, Shanghai 200065
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.